Targeted Therapy in Ovarian Cancer
Ovarian cancer (OC) is associated with a dismal prognosis and lack of curative treatment. Increased understanding of OC biology has led to the development of several targeted therapies, including antiangiogenic agents and poly(ADP-ribose) polymerase (PARP) inhibitors. Cell cycle inhibitors and endoc...
Saved in:
| Main Authors: | Marcus Vetter, Alexandra Leary |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2021-06-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2021.08.033 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comprehensive Review on PARP Inhibitors in Ovarian Cancer: A Breakthrough in Diagnostic and Therapeutic Approaches
by: Marcus Vetter, et al.
Published: (2023-10-01) -
Advancing Ovarian Cancer Treatment: The Latest Insights on PARP Inhibitors from ASCO 2023
by: Yves van Roon, et al.
Published: (2023-12-01) -
Targeting LMTK3 in ovarian cancer: A dual role in prognosis and therapy
by: Chrysa Filippopoulou, et al.
Published: (2024-12-01) -
ESMO Congress 2021 News: Update Systemic Therapy in Early and Advanced Breast Cancer
by: Marcus Vetter, et al.
Published: (2021-10-01) -
2021 Update on Systemic Therapy for Breast Cancer
by: Anton Oseledchyk, et al.
Published: (2022-03-01)